Café #21 – 15 juillet: « Importance des biomarqueurs, de la preuve de concept a la validation clinique »

Maxim MMaxime Moulard is CSO for BioCytex, a company that develops quantitative flow cytometry application kits. BioCytex is performing R&D and clinical investigations for major worldwide pharmaceutical companies. Biocytex is currently involved in developing diagnostic tools that can be used in a large spectrum of diseases including cancer, inflammatory diseases and hemostasis. Maxime has been involved in establishing and managing major corporate collaborations and partnerships (Eli Lilly, Sanofi-Aventis) as well as numerous academic and Institutional collaborations.
Prior to joining BioCytex in 2001, he was Visiting Scientist at The Scripps Research Institute (TSRI), in La Jolla, from 1998 to 2000. His scientific interests led him to develop new methods to generate and characterize human monoclonal antibodies using phage-display technologies. He received his Ph.D. in Biochemistry from the University Pierre & Marie Curie (Paris, France) and completed his post-doctoral training at the Institute für Virology in Marburg, Germany. He has published over 30 original manuscripts, book chapters, patents and reviews and has been a regular contributor of original research to the field of protein interaction and signaling mechanisms.

Votre commentaire

Entrez vos coordonnées ci-dessous ou cliquez sur une icône pour vous connecter:


Vous commentez à l’aide de votre compte Déconnexion /  Changer )

Photo Facebook

Vous commentez à l’aide de votre compte Facebook. Déconnexion /  Changer )

Connexion à %s